SecBot SecBot
8-K ·Filed Feb 25, 2026

CPRX

CATALYST PHARMACEUTICALS, INC.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001193125-26-071702
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The combination of strong revenue growth, significant margin expansion from royalty reductions, and solid cash generation makes CPRX a compelling growth story. Traders should monitor the execution of 2026 guidance and the outcome of the remaining FIRDAPSE patent litigation with Hetero USA.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$24.88
T+0 close · Feb 25, 2026 · via day close
Latest settled
+25.72%
T+60 · $31.28
Vs SPY
+17.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $24.88entry
  2. T+1 · 9mo ago −7.23%α −6.78% · $23.08
  3. T+5 · 9mo ago −2.25%α −1.12% · $24.32
  4. T+20 · 8mo ago −2.53%α +3.87% · $24.25
  5. T+60 · 6mo ago +25.72%α +17.97% · $31.28
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Catalyst Pharmaceuticals reported record financial results for Q4 and full year 2025, with total revenues of $589.0 million (up 19.8% YoY) and GAAP net income of $214.3 million (up 30.8% YoY), driven by strong growth in FIRDAPSE and AGAMREE. The company provided 2026 revenue guidance of $615–645 million and announced favorable royalty changes for FIRDAPSE that will improve margins starting in 2026.

Key Facts

  • Full year 2025 total revenues were $589.0 million, up 19.8% YoY
  • GAAP net income was $214.3 million, up 30.8% YoY
  • Q4 2025 revenues were $152.6 million, up 7.6% YoY
  • FIRDAPSE net revenue grew 17.1% YoY to $358.4 million in 2025
  • AGAMREE net revenue grew 154.3% YoY to $117.1 million in 2025
  • 2026 revenue guidance set at $615–645 million (up 11.1–16.4% from 2025)
  • FIRDAPSE royalty rate will drop from 18.5% to 6% starting January 26, 2026, significantly improving margins
  • Cash and cash equivalents increased 37% to $709.2 million as of December 31, 2025

Financial Impact

2026 revenue guidance of $615–645 million implies 11.1–16.4% growth; FIRDAPSE royalty reduction from 18.5% to 6% will significantly improve gross margins and profitability starting in 2026

revenueepsgross margincash flow

Risk Factors

  • Remaining patent litigation with Hetero USA, Inc. scheduled for trial on March 23, 2026
  • Decline in FYCOMPA revenue due to generic competition (down 17.4% in 2025)
  • Execution risk on business development strategy and potential acquisitions

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-071702
Document: d108222d8k.htm0001193125-26-071702
Document: 0001193125-26-071702-index-headers.html0001193125-26-071702
Document: 0001193125-26-071702-index.html0001193125-26-071702
Document: 0001193125-26-071702.txt0001193125-26-071702

Track record

16 reports on CPRX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +0.74% at T+20 after the May 28, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
  2. Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
  3. Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
  4. Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
  5. Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
  6. Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
  7. Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
  8. Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
  9. May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
  10. May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026